Phase 4 N=437 Fibrinogen in Haemorrhage of Delivery
Post-Partum Hemorrhage
Primary: Failure Rate of PPH Management — 75; 80; 92; 92 Participants — p=0.9563
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Presence or Absence of Blood in the GI Lumen
Upper GI Bleeding
Primary: Number of Participants With True Positive Results — 3 Participants
N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
N/A N=88 Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
Hemorrhage
Primary: CBC Hemoglobin Measurement Compared to Non-invasive Radical-7 Measurement — 10.7; 9.2 grams per deciliter
N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
N/A N=101 EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging
Hemorrhage · Bleeding Hemorrhage
Primary: Number of Participants With Clinical Success: Cessation of Bleeding up to 24 Hours — 100 Participants
Phase 1 N=27 HEMOBLAST Pilot Clinical Investigation
Hemostasis
Primary: Mean Paired Kappa Statistic for the Assignment of SBSS Scores by 2 Investigators — 0.7754 Kappa statistic
N/A N=99,659 A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth
Post-Partum Haemorrhage
Primary: The Primary Outcome is a Composite of the Following Three Clinical Outcomes: 1) Severe PPH Defined as Blood Loss ≥1000 ml or; 2) Postpartum Laparotomy for Bleeding or…
N/A N=258 HEMOBLAST Pivotal Clinical Investigation
Hemostasis
Primary: Proportion of Subjects Achieving Hemostasis — 148; 61 Participants — p=<0.0001
N/A N=24 Capsule Endoscopy for HEmorrhage in the ER
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
N/A N=106 Accuracy of Blood Loss Estimation After Vaginal Delivery
Postpartum Hemorrhage
Primary: Difference in Actual Blood Volume and Estimated Blood Volume in Milliliters. — -20.8; -41.7; -53.5; -96.0 milliliters — p=<0.05
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
N/A N=50 Diet and Hereditary Haemorrhagic Telangiectasia
Hereditary Haemorrhagic Telangiectasia (HHT)
Primary: Number of Participants That Achieving Personal Recommended Intake of Iron — 43 Participants
N/A N=100 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
Phase 2 N=33 A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Hemostasis · General Surgery
Primary: To Evaluate the Safety of sFilm-FS Versus an Active-comparator (TACHOSIL®) When Used as Adjunct to Conventional Hemostatic Techniques During Elective Surgery Through…
N/A N=62 Phlebotomy to Prevent Blood Loss in Major Hepatic Resections
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Phase 1 N=7 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
Phase 3 N=35 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes
N/A N=4 Temporary Aortic Occlusion With the Abdominal Tourniquet for Refractory Postpartum Haemorrhage: A Proof-of-Concept Study in a War-Affected Region
Postpartum Haemorrhage (PPH)
Primary: Time to Bleeding Control After AAJT-S Device Application — 2 Minutes
N/A N=156 Hereditary Haemorrhagic Telangiectasia Flight Safety Study
Hereditary Haemorrhagic Telangiectasia
Primary: HHT Patients Who by the Questionnaire Did or Did Not Self Report a Medical Complication During Flight — 77 percentage of patients
N/A N=30 Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING]
Upper GI Bleeding
Primary: Number of Participants With (Serious) Adverse Event Related to the Medical Device — 0 Participants
N/A N=20 Hemospray Versus the Combined Conventional Technique for Endoscopic Hemostasis of Bleeding Peptic Ulcers : A Pilot Study
Bleeding Peptic Ulcers
Primary: Re-bleeding Within 4 Weeks — 3; 1 Participants
Phase 3 N=40 The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study
Hemorrhage · Soft Tissue Bleeding · Hepatic Parenchyma Bleeding
Primary: Absolute Time to Haemostasis (TTH) — 4.0; 4.0 Minutes
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
N/A N=109 A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty
Arthritis
Primary: Transfusion Requirement — 1.6; 2.2 units
N/A N=235 Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
Phase 3 N=102 The EVARREST® Fibrin Sealant Patch Liver Study
Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization — 48; 24 participants with hemostatic success — p=<.0001
Phase 3 N=19 RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
Venous Thromboembolism · Menstruation
Primary: PBAC Scores — 292; 146 score on a scale
Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml